{"id":"NCT01144416","sponsor":"Organon and Co","briefTitle":"Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)","officialTitle":"A Phase 3, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a Single Injection of SCH 900962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women Aged 35 to 42 Years (Phase 3; Protocol No. P06029)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-07","completion":"2012-04","firstPosted":"2010-06-15","resultsPosted":"2012-12-27","lastUpdate":"2022-02-03"},"enrollment":1424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Infertility"],"interventions":[{"type":"BIOLOGICAL","name":"SCH 900962 / Corifollitropin alfa / Org 36286","otherNames":["MK-8962"]},{"type":"BIOLOGICAL","name":"RecFSH / follitropin beta","otherNames":["Follistim® AQ Cartridge"]},{"type":"DRUG","name":"Placebo for SCH 900962","otherNames":[]},{"type":"DRUG","name":"Placebo for recFSH","otherNames":[]}],"arms":[{"label":"Single injection of 150 µg SCH 900962 (MK-8962)","type":"EXPERIMENTAL"},{"label":"Daily 300 IU recFSH","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to show that a single injection of SCH 900962/MK-8962 is non-inferior to daily injections of recombinant follicle-stimulating hormone (recFSH) during the first week of ovarian stimulation in terms of the number of vital pregnancies (ie, presence of at least one fetus with heart activity as assessed by ultrasound at least 35 days after embryo transfer) in women aged 35 to 42 years undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).","primaryOutcome":{"measure":"Percentage of Participants With a Vital Pregnancy","timeFrame":"Vital pregnancy will be assessed by ultrasound at least 35 days after embryo transfer (with a timeframe of 35-42 days). Time from start of study treatment to embryo transfer is maximally 24 days.","effectByArm":[{"arm":"Single Injection of 150 µg SCH 900962/MK-8962","deltaMin":23.9,"sd":null},{"arm":"Daily 300 IU recFSH","deltaMin":26.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"35 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26003273","27619773","26991902","26520396"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":692},"commonTop":["PROCEDURAL PAIN","HEADACHE","POST PROCEDURAL COMPLICATION","PELVIC DISCOMFORT","NAUSEA"]}}